_256_384.jpg)
News | September 17, 2021
Promising prospects for Indian pharma: CLSA
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
ABB Drives play a key role in the cleanroom infrastructure of Bharat Biotech, India’s first indigenous Covid-19 vaccine manufacturer. The drives are easy to commission, use and ensure higher energy efficiency
At present 18 per cent of the local pharmaceutical market is under government's price control
Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The facility has the capacity to produce one crore doses per day
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
Subscribe To Our Newsletter & Stay Updated
